Michael Foote, MD, Memorial Sloan Kettering Cancer Center, discusses the final results from the CheckMate 8HW trial, including the three study arms: nivolumab plus ipilimumab, nivolumab alone, and standard chemotherapy.

The FDA recently approved nivolumab plus ipilimumab for patients with mismatch repair-deficient stage IV colorectal cancer based on these study results.